Table 3.
The Efficacy of Recombinant Adjuvant Subunit Vaccine (Shingrix®) in Adults Grouped by Age
| Characteristic | ZOE-50 | ZOE-70 |
|---|---|---|
| Study population | n = 14,411 Age: ≥ 50 yr |
n = 13,900 Age: ≥ 70 yr |
| Median follow-up | 3.2 yr | 3.7 yr |
| HZ risk reduction (%) | Overall: 97.2 | Overall: 89.8 |
| 50-59 yr: 96.6 | ||
| 60-69 yr: 97.4 | ||
| ≥ 70 yr: 97.9 | ||
| PHN risk reduction (%) | ≥ 50 yr: 91.2 | ≥ 70 yr: 88 |
| Vaccine-related SAE | n = 1 (vs. n = 3 in placebo) | n = 12 (vs. n = 8 in placebo) |
ZOE: study done on the efficacy and safety of the herpes zoster recombinant subunit vaccine, HZ: herpes zoster, PHN: postherpetic neuralgia, SAE: systemic adverse effects.